WO2021261870A1 - Composition comprising 6'-hydroxy justcidin-b, for preventing, ameliorating or treating allergic diseases - Google Patents

Composition comprising 6'-hydroxy justcidin-b, for preventing, ameliorating or treating allergic diseases Download PDF

Info

Publication number
WO2021261870A1
WO2021261870A1 PCT/KR2021/007775 KR2021007775W WO2021261870A1 WO 2021261870 A1 WO2021261870 A1 WO 2021261870A1 KR 2021007775 W KR2021007775 W KR 2021007775W WO 2021261870 A1 WO2021261870 A1 WO 2021261870A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxy
justicidin
allergic
composition
preventing
Prior art date
Application number
PCT/KR2021/007775
Other languages
French (fr)
Korean (ko)
Inventor
윤주병
이현용
염지현
김승환
전지현
정태성
허운
황연하
이마세
Original Assignee
동화약품주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동화약품주식회사 filed Critical 동화약품주식회사
Publication of WO2021261870A1 publication Critical patent/WO2021261870A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy

Definitions

  • the present invention relates to a composition comprising 6'-hydroxy justicidin-B as an active ingredient.
  • the present invention relates to a pharmaceutical composition for preventing or treating allergic diseases comprising 6'-hydroxy justicidin-B as an active ingredient.
  • the present invention relates to a food composition for preventing or improving allergic diseases containing 6'-hydroxy justicidin-B.
  • the present invention relates to a cosmetic composition for preventing or improving allergic diseases comprising 6'-hydroxy justicidin-B as an active ingredient.
  • 6'-hydroxyjusticidin-B is also one of the lignan-based compounds present in Rathornwort. Although there is a difference in efficacy and superiority with other lignan-based drugs depending on the type of cancer cell line, the cytotoxic effect in various cancer cells, etc. is known (Cytotoxic activity of lignans from Justicia procumbens, Hong Jin et al, Fitorick, 2014;94:70-6).
  • Allergy is defined as a phenomenon in which a living body in contact with a foreign substance called an allergen exhibits a different reaction from the normal to the substance. Allergies can be caused not only by various allergens such as pollen, drugs, vegetable fibers, bacteria, food, hair dye, and chemicals, but also by humidity, temperature, and exercise. , allergic otitis media, allergic enteritis, anaphylaxis and urticaria.
  • Th2 lymphocytes which are activated by Th2 lymphocytes and contain several bioactive substances (cytokines) such as interleukin-4 (IL-4) or interleukin-5 (IL-5). and these physiologically active substances stimulate B lymphocytes to promote IgE antibody secretion (Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene, Shimoda K et al, Nature 1996;380 ( 6575):630-3).
  • the secreted IgE antibody binds to FceR1 on the surface of cells such as mast cells and basophils and activates these cells.
  • Activated cells promote secretion of various physiologically active substances as well as histamine, leukotriene, and prostaglandin D2 through degranulation, resulting in various allergic reactions such as vasodilation, smooth muscle contraction, and mucous secretion.
  • One object of the present invention is to provide a pharmaceutical composition for preventing or treating allergic diseases comprising 6'-hydroxy justicidin-B as an active ingredient.
  • One object of the present invention is to provide a food composition for preventing or improving allergic diseases, comprising 6'-hydroxy justicidin-B as an active ingredient.
  • One object of the present invention is to provide a cosmetic composition for preventing or improving allergic diseases, comprising 6'-hydroxy justicidin-B as an active ingredient.
  • One object of the present invention is to provide a method for preventing, improving or treating an allergic disease, comprising administering to a subject in need thereof 6'-hydroxy justicidin-B or a composition comprising the same as an active ingredient will be.
  • One object of the present invention is to provide a use of 6'-hydroxy justicidin-B or a composition comprising the same for the prevention, improvement, or treatment of allergic diseases.
  • One object of the present invention is to provide a use of 6'-hydroxy justicidin-B or a composition comprising the same for the preparation of a medicament for the prevention, improvement, or treatment of allergic diseases.
  • the present invention provides a pharmaceutical composition for preventing or treating allergic diseases, comprising 6'-hydroxy justicidin-B as an active ingredient.
  • the allergic disease may be any one or more selected from the group consisting of allergic rhinitis, allergic asthma, allergic conjunctivitis, atopic dermatitis, allergic enteritis, allergic otitis media, anaphylaxis, and urticaria.
  • the pharmaceutical composition may contain 0.1 mg/g to 200 mg/g of 6'-hydroxy justicidin-B.
  • the pharmaceutical composition may include only 6'-hydroxy justicidin-B as an active ingredient.
  • 6'-hydroxy justicidin-B shows excellent bioavailability in the human body when administered orally. Accordingly, the pharmaceutical composition of an embodiment comprising 6'-hydroxy justicidin-B may exhibit excellent bioavailability.
  • the present invention provides a food composition for preventing or improving allergic diseases, comprising 6'-hydroxy justicidin-B as an active ingredient.
  • the food composition may be a health functional food.
  • the food composition may be a beverage.
  • the present invention provides a cosmetic composition for preventing or improving allergic diseases, comprising 6'-hydroxy justicidin-B as an active ingredient.
  • the present invention provides a method for preventing, ameliorating or treating an allergic disease, comprising administering to a subject in need thereof 6'-hydroxy justicidin-B or a composition comprising the same as an active ingredient.
  • the composition may be a pharmaceutical composition, a food composition and/or a cosmetic composition of the present invention.
  • the present invention provides a method for preventing or treating an allergic disease, comprising administering 6'-hydroxy justicidin-B or a pharmaceutical composition comprising the same as an active ingredient to a subject in need thereof.
  • the present invention provides a method for preventing or improving an allergic disease, comprising administering to a subject in need thereof 6'-hydroxy justicidin-B or a food composition comprising the same as an active ingredient.
  • the present invention provides a method for preventing or improving an allergic disease, comprising applying 6'-hydroxy justicidin-B or a cosmetic composition comprising the same as an active ingredient to a subject in need thereof.
  • the present invention provides the use of 6'-hydroxy justicidin-B or a composition comprising the same for the prevention, improvement, or treatment of allergic diseases.
  • the composition may be a pharmaceutical composition, a food composition and/or a cosmetic composition of the present invention.
  • the present invention provides the use of 6'-hydroxy justicidin-B or a pharmaceutical composition comprising the same for the prevention or treatment of allergic diseases.
  • the present invention provides the use of 6'-hydroxy justicidin-B or a food composition or cosmetic composition comprising the same for the prevention or improvement of allergic diseases.
  • the present invention provides the use of 6'-hydroxy justicidin-B or a composition comprising the same for the preparation of a medicament for the prevention, improvement, or treatment of allergic diseases.
  • the composition may be a pharmaceutical composition, a food composition and/or a cosmetic composition of the present invention.
  • the present invention provides the use of 6'-hydroxy justicidin-B or a pharmaceutical composition comprising the same for the preparation of a medicament for the prevention, improvement or treatment of allergic diseases.
  • the present invention provides a use of 6'-hydroxy justicidin-B or a food composition or cosmetic composition comprising the same for the preparation of a medicament for the prevention or improvement of allergic diseases.
  • 6'-hydroxy justicidin-B may be synthesized through organic synthesis.
  • 6'-hydroxy justicidin-B of the present invention can inhibit the secretion of Th2 inflammatory cytokines, and exhibits an allergic asthma inhibitory effect and an anaphylactic inhibitory effect, and thus effectively prevents, treats or improves allergic diseases can do.
  • the allergic disease may include, without limitation, various diseases caused by various triggers.
  • the allergic disease may be one or more selected from the group consisting of allergic rhinitis, allergic asthma, allergic conjunctivitis, atopic dermatitis, allergic enteritis, allergic otitis media, anaphylaxis, and urticaria.
  • the allergic disease may be an allergic respiratory disease.
  • the term "subject" refers to an animal, typically a mammal capable of exhibiting a beneficial effect by treatment with the composition of the present invention.
  • mammal mammals, including humans, and the term “administering” means providing a given substance to a subject by any suitable method. It is apparent to those skilled in the art that the therapeutically effective dosage and frequency of administration for the active ingredient of the present invention will vary depending on the desired effect.
  • mamal including humans refers to mammals such as monkeys, cattle, horses, dogs, cats, rabbits, rats, and mice, and in particular includes humans. Also, such subjects include all subjects having or at risk of having symptoms of allergic disease.
  • prevention means delaying the onset of a disease, disorder or condition. Prevention may be considered complete if the onset of the disease, disorder or condition is delayed for a predetermined period.
  • the term “amelioration” means partially or completely alleviating, alleviating, inhibiting or delaying the onset of a disease, disorder or condition, reducing the severity, or reducing the occurrence of one or more symptoms or features. .
  • treatment refers to partially or completely alleviating, ameliorating, alleviating, inhibiting or delaying the onset of a particular disease, disorder and/or condition, reducing the severity, or preventing the occurrence of one or more symptoms or features. means to reduce
  • the pharmaceutical composition of the present invention is in the form of tablets, pills, powders, granules, capsules, suspensions, internal solutions, emulsions, syrups, aerosols, injection solutions, etc. according to conventional methods for preventing and treating allergic diseases. It can be formulated and used.
  • carriers, excipients and diluents that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • it is prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
  • composition of the present invention may be administered orally or parenterally (eg, application or intravenous, subcutaneous, intraperitoneal injection).
  • oral administration is a method of injecting a drug by mouth for alleviating pathological symptoms
  • parenteral administration refers to subcutaneous, intramuscular, It refers to a method of intraperitoneal administration using an intravenous or tube.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the complex composition, for example, starch, calcium carbonate, sucrose, lactose, gelatin, etc. It can be prepared by mixing. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.
  • Liquid formulations for oral administration include suspensions, internal solutions, emulsions, syrups, etc., and various excipients, for example, wetting agents, sweeteners, fragrances, preservatives, etc. in addition to commonly used simple diluents such as water and liquid paraffin. can be used
  • Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like.
  • non-aqueous solvent and suspending agent vegetable oils such as propylene glycol, polyethylene glycol, and olive oil, and injectable esters such as ethyl oleate may be used.
  • the pharmaceutical composition of the present invention may further include a carrier, excipient or diluent.
  • Carriers, excipients or diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, hydroxy Minerals such as propyl methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxy benzoate, ethyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate, silicon dioxide, etc. may be used. .
  • the pharmaceutically acceptable additive according to the present invention may be included in an amount of 0.1 to 99.9 parts by weight based on the composition, specifically, 0.1 to 50 parts by weight, but the embodiment is not limited thereto.
  • the dosage of the pharmaceutical composition according to the present invention should be a pharmaceutically effective amount.
  • “Pharmaceutically effective amount” means an amount sufficient to prevent or treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level includes the formulation method, the patient's condition and weight, the patient's sex, and age. , can be variously selected by those skilled in the art according to factors such as the degree of disease, drug form, administration route and duration, excretion rate, reaction sensitivity, and the like. An effective amount will vary depending on the route of treatment, the use of excipients, and the potential for use with other agents, as will be appreciated by those skilled in the art.
  • An amount effective to prevent or treat an allergic disease is administered in single or multiple doses, alone or in combination with one or more other compositions (such as other therapeutic agents for allergic diseases), which provides the desired performance or objective or subjective benefit in the subject. It can mean quantity.
  • the dosage or dosage of the pharmaceutical composition according to the present invention varies depending on the patient's weight, age, sex, health status, diet, administration time, administration method, excretion rate, and severity of disease, but is 0.001 on an adult basis mg/kg to 1000 mg/kg may be administered in one to several divided doses.
  • a cosmetic composition for preventing or improving allergic diseases comprising 6'-hydroxy justicidin-B as an active ingredient.
  • the cosmetic composition is a softening lotion, astringent lotion, nutrient lotion, nutrition cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, It may be a formulation selected from the group consisting of body oil, body essence, makeup base, foundation, hair dye, shampoo, conditioner and body cleanser.
  • the cosmetic composition of the present invention can be prepared in various forms according to a conventional cosmetic preparation method using the 6'-hydroxy justicidin-B, and a stabilizer, solubilizer, It may contain conventional adjuvants such as vitamins, pigments, and flavorings.
  • the cosmetic composition is prepared in the form of cosmetic products containing the 6'-hydroxy justicidin-B, shampoo, hair lotion, hair cream, hair gel, etc. It can be used after dilution.
  • the cosmetic composition of the present invention is particularly preferably prepared in the form of a lotion, lotion, cream, or essence.
  • 6'-hydroxy justicidin-B may be added to the cosmetic in an amount of 0.1% to 10% by weight based on the total liquid weight, and 0.001 to about the total dry weight of the cosmetic composition. It may be added to the cosmetic in an amount of 5% by weight, preferably 0.01 to 3% by weight.
  • the 6'-hydroxy justicidin-B of the present invention excellently inhibited the differentiation of Th2 cells related to allergic diseases, and was effective in inhibiting asthma diseases even when administered at low concentrations in the Balb/c mouse model of allergic asthma. shows an excellent effect. Accordingly, the pharmaceutical composition, food composition, and cosmetic composition comprising 6'-hydroxy justicidin-B according to the present invention can be widely used as an agent for preventing, treating or improving allergic diseases.
  • 1 is a diagram showing the chemical structure of 6'-hydroxy justicidin-B according to the present invention.
  • 6'-hydroxy justicidin-B was synthesized through the following process.
  • the structure of 6'-hydroxy justicidin-B is as shown in FIG. 1 .
  • Step 1 6,7-dimethoxy-3-oxo-1,3-dihydronaphtho [2,3-c] furan-4-yl trifluoromethanesulfonate (3.0 g, 7.65 mmol) was mixed with dioxane (90ml) After dissolving in a solvent, 5-methoxymethoxy-6-(4,4,5,5,-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzo[1 ,3]dioxole (2.83g, 9.18mmol), [1,1'-bis(diphenyl phosphino)ferrocene]dichloropalladium(II) (1.12g, 1.53mmol) and lithium hydroxide monohydrate (642mg, 15.3mmol) ) were sequentially added under a nitrogen atmosphere.
  • Step 2 6,7-dimethoxy-9-(6-methoxymethoxy-benzo[1,3]dioxol-5-yl)-3H-naphtho[2,3-c]furan-1-one (8g, 18.9mmol) was dissolved in ethanol (80ml), and 44ml of 12M HCl was added dropwise, followed by reaction at 50°C for 12 hours. After the reaction was completed, 100 ml of water was added, and the mixture was extracted with dichloromethane (200 ml, 100 ml, 50 ml). The obtained organic layer was washed with water (150ml) and brine (100ml), dried over anhydrous Na 2 SO 4 , filtered and concentrated.
  • Example 1 Comparative experiment on the effect of inhibiting differentiation from CD4 T cells to Th2 cells
  • interleukin-2 20 ng/mL of interleukin-2 (IL-2) was additionally treated, and to induce Th0 cells into Th2 cells, 20 ng/mL of interleukin-2 (IL-2), 100 ng/mL of interleukin-4 (IL-4), 10 ⁇ g/mL of interferon-gamma antibody (anti-IFN ⁇ antibody), 10 ⁇ g/mL of interleukin-12 antibody (anti-IL12 antibody) was added, and at this time, 6'-hydroxy justicidin-B prepared in Preparation Example 1 was treated. The medium of the 24-well plate was used to measure the secretion level of interleukin-5 (IL-5), a Th2 inflammatory cytokine.
  • IL-5 interleukin-5
  • Th2 inflammatory cytokine 6'-hydroxy justicidin-B prepared in Preparation Example 1
  • the excellent inhibitory effect on interleukin-5 secretion of 6'-hydroxy justicidin-B is confirmed.
  • 6'-hydroxy justicidin-B achieves an excellent IL-5 secretion inhibitory effect even at a low concentration. From this, the excellent inhibitory effect of 6'-hydroxy justicidin-B into Th2 cells and the excellent prevention, improvement, or therapeutic effect of 6'-hydroxy justicidin-B on allergic diseases were confirmed. .
  • Blood and lung lavage were obtained by autopsy 5 hours after the final sensitization (day 30), and lung tissue was fixed in 10% neutral formalin. After that, blood and lung lavage were used for IgE and Th2 cytokines and immune cytometry, and the lung tissue was cut to make a slide, and the tissue was observed by performing H&E staining. Observation of lung tissue was photographed at 400 times the microscope, and the thickness of the lung epithelium of the photographed tissue was measured using the Image-pro Plus 6.0 program. The results are shown in Tables 2 and 3, and the inhibitory ability was calculated using [Equation 1] described above in Example 1.
  • 6-week-old ICR mice were grouped based on body weight, and anaphylaxis was induced by intraperitoneal administration of Compound 48/80 (Sigma #C2313) at a concentration of 16 mg/kg.
  • Compound 48/80 Sigma #C2313
  • the 6'-hydroxy justicidin-B and the positive control group DSCG (Cromolyn sodium, Sigma #C0399) 250 mg/kg were administered intraperitoneally 1 hour before anaphylaxis induction, respectively, and mortality (mortality) for 30 minutes after anaphylaxis induction. ) was observed, and the results are shown in Table 4.
  • Anaphylaxis inhibitory ability was calculated using the following [Equation 2].
  • the above ingredients are mixed and filled in an airtight bag to prepare a powder.
  • tablets are prepared by tableting according to a conventional manufacturing method of tablets.
  • the above ingredients are mixed and filled in a gelatin capsule to prepare a capsule.
  • the content of the above ingredients per 1 ampoule (2 ml) is prepared.
  • the above ingredients are mixed and filled in a container.
  • Vitamin B6 0.5 mg
  • composition ratio of the above vitamin and mineral mixture is mixed composition with ingredients suitable for health functional food as a preferred embodiment, but the mixing ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health functional food manufacturing method.
  • a health functional food composition eg, nutritional candy, etc.
  • the resulting solution is filtered and acquired in a sterilized 2L container, sealed and sterilized, then refrigerated. It is used to prepare the health functional beverage composition of the present invention.
  • the composition ratio is prepared by mixing ingredients suitable for relatively favorite beverages in a preferred embodiment, the blending ratio may be arbitrarily modified according to regional and national preferences such as demand class, demanding country, and use purpose.
  • the above ingredients were mixed to prepare a cosmetic.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating allergic diseases, or a food composition for ameliorating allergic diseases, comprising 6'-hydroxy Justicidin-B as an active ingredient. 6'-hydroxy Justicidin-B of the present invention exhibited an excellent Th2 cytokine inhibitory effect, and exhibited an excellent anti-allergic asthmatic effect. Also, it is confirmed that 6'-hydroxy Justicidin-B has an excellent anaphylaxis inhibitory effect. Accordingly, it is possible to effectively prevent, treat, or ameliorate allergic diseases by using 6'-hydroxy Justicidin-B as an active ingredient.

Description

6'-하이드록시 저스티시딘-B(6'-HYDROXY JUSTICIDIN B)를 포함하는 알레르기성 질환의 예방, 개선 또는 치료용 조성물 Composition for preventing, improving or treating allergic diseases comprising 6'-hydroxy justicidin-B (6'-HYDROXY JUSTICIDIN B)
본 발명은 6'-하이드록시 저스티시딘-B를 유효성분으로 포함하는 조성물에 관한 것이다.The present invention relates to a composition comprising 6'-hydroxy justicidin-B as an active ingredient.
보다 구체적으로, 본 발명은 6'-하이드록시 저스티시딘-B를 유효성분으로 포함하는 알레르기성 질환의 예방 또는 치료용 약학적 조성물에 관한 것이다.More specifically, the present invention relates to a pharmaceutical composition for preventing or treating allergic diseases comprising 6'-hydroxy justicidin-B as an active ingredient.
보다 구체적으로, 본 발명은 6'-하이드록시 저스티시딘-B를 포함하는 알레르기성 질환의 예방 또는 개선용 식품 조성물에 관한 것이다.More specifically, the present invention relates to a food composition for preventing or improving allergic diseases containing 6'-hydroxy justicidin-B.
보다 구체적으로, 본 발명은 6'-하이드록시 저스티시딘-B를 유효성분으로 포함하는 알레르기성 질환의 예방 또는 개선용 화장료 조성물에 관한 것이다.More specifically, the present invention relates to a cosmetic composition for preventing or improving allergic diseases comprising 6'-hydroxy justicidin-B as an active ingredient.
쥐꼬리망초(Justicia procumbens)에는 많은 리그난(Lignan) 계열의 화합물들이 있으며, 이들 화합물들은 암세포의 세포 독성 및 증식 억제 작용, 항바이러스 작용 등의 약리효과가 알려져 있다 (Justicidin B: A promising Bioactive Lignan, Shiva Hemmati and Hassan Seradj, Molecules, 2016;21(7):820).There are many lignan (Lignan)-based compounds in Rat-tail ( Justicia procumbens ), and these compounds are known to have pharmacological effects such as cytotoxicity and proliferation inhibitory action of cancer cells, antiviral action, etc. (Justicidin B: A promising Bioactive Lignan, Shiva Hemmati and Hassan Seradj, Molecules, 2016;21(7):820).
6'-하이드록시 저스티시딘-B는 역시 쥐꼬리망초에 존재하는 리그난 계열의 화합물 중 하나로, 암 세포주 종류에 따라 다른 리그난 계열 약물과의 약효 우위성에서는 차이가 있지만, 여러 암세포에서의 세포 독성 효과 등이 알려져 있다 (Cytotoxic activity of lignans from Justicia procumbens, Hong Jin et al, Fitoterapia, 2014;94:70-6).6'-hydroxyjusticidin-B is also one of the lignan-based compounds present in Rathornwort. Although there is a difference in efficacy and superiority with other lignan-based drugs depending on the type of cancer cell line, the cytotoxic effect in various cancer cells, etc. is known (Cytotoxic activity of lignans from Justicia procumbens, Hong Jin et al, Fitoterapia, 2014;94:70-6).
알레르기는 알레르겐이라고 불리우는 외래성 물질과 접한 생체가 그 물질에 대하여 정상과 다른 반응을 나타내는 현상이라고 정의된다. 알레르기는 꽃가루, 약물, 식물성 섬유, 세균, 음식물, 염색약, 화학물질 등의 다양한 알레르겐들 뿐만 아니라 습도, 온도, 운동 등에 의해서도 유발될 수 있으며, 이로 인해 알레르기성 비염, 천식, 아토피 피부염, 알레르기성 결막염, 알레르기성 중이염, 알레르기성 장관염, 아나필락시스 및 두드러기와 같은 여러 질환들이 야기될 수 있다. Allergy is defined as a phenomenon in which a living body in contact with a foreign substance called an allergen exhibits a different reaction from the normal to the substance. Allergies can be caused not only by various allergens such as pollen, drugs, vegetable fibers, bacteria, food, hair dye, and chemicals, but also by humidity, temperature, and exercise. , allergic otitis media, allergic enteritis, anaphylaxis and urticaria.
다른 염증 반응과는 달리 알레르기성 염증 반응은 주로 Th2 림프구에 의해 일어나는데, 활성화된 Th2 림프구가 인터류킨-4(IL-4) 또는 인터류킨-5 (IL-5)와 같은 여러 생리활성 물질들 (cytokines)을 분비하고 이들 생리활성 물질들이 B 림프구를 자극하여 IgE 항체 분비가 촉진된다 (Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene, Shimoda K et al, Nature 1996;380(6575):630-3). 분비된 IgE 항체는 비만세포(mast cell)나 호염기구(basophil) 등의 세포 표면에 있는 FceR1과 결합하여 이들 세포를 활성화시킨다. 활성화된 세포들은 탈과립을 통해 여러 생리활성 물질들뿐만 아니라 히스타민, 류코트리엔, 프로스타글란딘 D2 등의 분비를 촉진시켜 혈관이완 (vasodilation), 평활근 수축 (smooth muscle contraction), 점액분비 (mucous secretion) 등의 여러 알레르기성 질환 및 기도 염증, 기도수축 등과 같은 여러 호흡기 질환과 관련된 반응들을 일으키는 것으로 알려져 있다 (Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and no-asthmatic subjects, Bjφrck T and Dahlen SE, Pulm Pharmacol 1993;6(1):87-96), (IgE, Mast Cells, Basophils, and Eosinophils, Stone KD et al, Journal of Allergy and Clinical Immunology, 125(2), S73-S80, 2010).Unlike other inflammatory responses, allergic inflammatory responses are mainly caused by Th2 lymphocytes, which are activated by Th2 lymphocytes and contain several bioactive substances (cytokines) such as interleukin-4 (IL-4) or interleukin-5 (IL-5). and these physiologically active substances stimulate B lymphocytes to promote IgE antibody secretion (Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene, Shimoda K et al, Nature 1996;380 ( 6575):630-3). The secreted IgE antibody binds to FceR1 on the surface of cells such as mast cells and basophils and activates these cells. Activated cells promote secretion of various physiologically active substances as well as histamine, leukotriene, and prostaglandin D2 through degranulation, resulting in various allergic reactions such as vasodilation, smooth muscle contraction, and mucous secretion. It is known to elicit reactions associated with sexual and respiratory diseases such as airway inflammation and airway constriction (Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and no-asthmatic subjects, Bjφrck T and Dahlen SE, Pulm Pharmacol 1993;6(1):87-96), (IgE, Mast Cells, Basophils, and Eosinophils, Stone KD et al, Journal of Allergy and Clinical Immunology, 125(2), S73-S80, 2010 ).
하지만, 현재 알레르기성 질환의 다양한 증상을 동시에 완화시켜 주는 경구용 치료제들은 매우 한정적이기 때문에 안전성이 확보되고 효능이 개선된 경구용 약물의 개발이 요구되고 있으며, 다중 기전의 특징을 갖고 있는 생약에서 유래한 활성 화합물이 알레르기성 질환 치료에 있어서 적합한 소재라 할 것이다. However, current oral therapeutic agents that simultaneously relieve various symptoms of allergic diseases are very limited, so the development of oral drugs with improved efficacy and safety is required. One active compound would be a suitable material for the treatment of allergic diseases.
본 발명의 일 목적은 6'-하이드록시 저스티시딘-B를 유효성분으로 포함하는 알레르기성 질환의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.One object of the present invention is to provide a pharmaceutical composition for preventing or treating allergic diseases comprising 6'-hydroxy justicidin-B as an active ingredient.
본 발명의 일 목적은 6'-하이드록시 저스티시딘-B를 유효성분으로 포함하는, 알레르기성 질환의 예방 또는 개선용 식품 조성물을 제공하는 것이다.One object of the present invention is to provide a food composition for preventing or improving allergic diseases, comprising 6'-hydroxy justicidin-B as an active ingredient.
본 발명의 일 목적은 6'-하이드록시 저스티시딘-B를 유효성분으로 포함하는, 알레르기성 질환의 예방 또는 개선용 화장료 조성물을 제공하는 것이다.One object of the present invention is to provide a cosmetic composition for preventing or improving allergic diseases, comprising 6'-hydroxy justicidin-B as an active ingredient.
본 발명의 일 목적은 6'-하이드록시 저스티시딘-B 또는 이를 유효성분으로 포함하는 조성물을 이를 필요로 하는 대상체에게 투여함을 포함하는 알레르기성 질환을 예방, 개선 또는 치료하는 방법을 제공하는 것이다.One object of the present invention is to provide a method for preventing, improving or treating an allergic disease, comprising administering to a subject in need thereof 6'-hydroxy justicidin-B or a composition comprising the same as an active ingredient will be.
본 발명의 일 목적은 알레르기성 질환의 예방, 개선, 또는 치료를 위한 6'-하이드록시 저스티시딘-B 또는 이를 포함하는 조성물의 용도를 제공하는 것이다.One object of the present invention is to provide a use of 6'-hydroxy justicidin-B or a composition comprising the same for the prevention, improvement, or treatment of allergic diseases.
본 발명의 일 목적은 알레르기성 질환의 예방, 개선, 또는 치료용 약제의 제조를 위한 6'-하이드록시 저스티시딘-B 또는 이를 포함하는 조성물의 용도를 제공하는 것이다.One object of the present invention is to provide a use of 6'-hydroxy justicidin-B or a composition comprising the same for the preparation of a medicament for the prevention, improvement, or treatment of allergic diseases.
본 발명은, 6'-하이드록시 저스티시딘-B를 유효성분으로 포함하는, 알레르기성 질환의 예방 또는 치료용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating allergic diseases, comprising 6'-hydroxy justicidin-B as an active ingredient.
일 실시예에서, 상기 알레르기성 질환은 알레르기성 비염, 알레르기성 천식, 알레르기성 결막염, 아토피 피부염, 알레르기성 장관염, 알레르기성 중이염, 아나필락시스 및 두드러기로 이루어진 군에서 선택된 어느 하나 이상일 수 있다.In one embodiment, the allergic disease may be any one or more selected from the group consisting of allergic rhinitis, allergic asthma, allergic conjunctivitis, atopic dermatitis, allergic enteritis, allergic otitis media, anaphylaxis, and urticaria.
일 실시예에서, 상기 약학적 조성물은 6'-하이드록시 저스티시딘-B를 0.1mg/g 내지 200mg/g 포함하는 것일 수 있다.In one embodiment, the pharmaceutical composition may contain 0.1 mg/g to 200 mg/g of 6'-hydroxy justicidin-B.
일 실시예에서, 상기 약학적 조성물은 유효성분으로 6'-하이드록시 저스티시딘-B만을 포함할 수 있다.In one embodiment, the pharmaceutical composition may include only 6'-hydroxy justicidin-B as an active ingredient.
6'-하이드록시 저스티시딘-B는 경구 투여 시 인체에서 우수한 생체 이용률을 보인다. 따라서, 6'-하이드록시 저스티시딘-B를 포함하는 일 실시예의 약학적 조성물은 우수한 생체 이용률을 나타낼 수 있다.6'-hydroxy justicidin-B shows excellent bioavailability in the human body when administered orally. Accordingly, the pharmaceutical composition of an embodiment comprising 6'-hydroxy justicidin-B may exhibit excellent bioavailability.
본 발명은 6'-하이드록시 저스티시딘-B를 유효성분으로 포함하는, 알레르기성 질환의 예방 또는 개선용 식품 조성물을 제공한다.The present invention provides a food composition for preventing or improving allergic diseases, comprising 6'-hydroxy justicidin-B as an active ingredient.
상기 식품 조성물은 건강기능식품일 수 있다. 상기 식품 조성물은 음료일 수 있다.The food composition may be a health functional food. The food composition may be a beverage.
본 발명은 6'-하이드록시 저스티시딘-B를 유효성분으로 포함하는, 알레르기성 질환의 예방 또는 개선용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for preventing or improving allergic diseases, comprising 6'-hydroxy justicidin-B as an active ingredient.
본 발명은 6'-하이드록시 저스티시딘-B 또는 이를 유효성분으로 포함하는 조성물을 이를 필요로 하는 대상체에게 투여함을 포함하는 알레르기성 질환을 예방, 개선 또는 치료하는 방법을 제공한다.The present invention provides a method for preventing, ameliorating or treating an allergic disease, comprising administering to a subject in need thereof 6'-hydroxy justicidin-B or a composition comprising the same as an active ingredient.
상기 조성물은 본 발명의 약학적 조성물, 식품 조성물 및/또는 화장료 조성물일 수 있다.The composition may be a pharmaceutical composition, a food composition and/or a cosmetic composition of the present invention.
본 발명은 6'-하이드록시 저스티시딘-B 또는 이를 유효성분으로 포함하는 약학적 조성물을 이를 필요로 하는 대상체에게 투여함을 포함하는 알레르기성 질환을 예방 또는 치료하는 방법을 제공한다.The present invention provides a method for preventing or treating an allergic disease, comprising administering 6'-hydroxy justicidin-B or a pharmaceutical composition comprising the same as an active ingredient to a subject in need thereof.
본 발명은 6'-하이드록시 저스티시딘-B 또는 이를 유효성분으로 포함하는 식품 조성물을 이를 필요로 하는 대상체에게 투여함을 포함하는 알레르기성 질환을 예방 또는 개선하는 방법을 제공한다.The present invention provides a method for preventing or improving an allergic disease, comprising administering to a subject in need thereof 6'-hydroxy justicidin-B or a food composition comprising the same as an active ingredient.
본 발명은 6'-하이드록시 저스티시딘-B 또는 이를 유효성분으로 포함하는 화장료 조성물을 이를 필요로 하는 대상체에게 적용함을 포함하는 알레르기성 질환을 예방 또는 개선하는 방법을 제공한다.The present invention provides a method for preventing or improving an allergic disease, comprising applying 6'-hydroxy justicidin-B or a cosmetic composition comprising the same as an active ingredient to a subject in need thereof.
본 발명은 알레르기성 질환의 예방, 개선, 또는 치료를 위한 6'-하이드록시 저스티시딘-B 또는 이를 포함하는 조성물의 용도를 제공한다.The present invention provides the use of 6'-hydroxy justicidin-B or a composition comprising the same for the prevention, improvement, or treatment of allergic diseases.
상기 조성물은 본 발명의 약학적 조성물, 식품 조성물 및/또는 화장료 조성물일 수 있다.The composition may be a pharmaceutical composition, a food composition and/or a cosmetic composition of the present invention.
본 발명은 알레르기성 질환의 예방 또는 치료를 위한 6'-하이드록시 저스티시딘-B 또는 이를 포함하는 약학적 조성물의 용도를 제공한다.The present invention provides the use of 6'-hydroxy justicidin-B or a pharmaceutical composition comprising the same for the prevention or treatment of allergic diseases.
본 발명은 알레르기성 질환의 예방 또는 개선을 위한 6'-하이드록시 저스티시딘-B 또는 이를 포함하는 식품 조성물 또는 화장료 조성물의 용도를 제공한다.The present invention provides the use of 6'-hydroxy justicidin-B or a food composition or cosmetic composition comprising the same for the prevention or improvement of allergic diseases.
본 발명은 알레르기성 질환의 예방, 개선, 또는 치료용 약제의 제조를 위한 6'-하이드록시 저스티시딘-B 또는 이를 포함하는 조성물의 용도를 제공한다.The present invention provides the use of 6'-hydroxy justicidin-B or a composition comprising the same for the preparation of a medicament for the prevention, improvement, or treatment of allergic diseases.
상기 조성물은 본 발명의 약학적 조성물, 식품 조성물 및/또는 화장료 조성물일 수 있다.The composition may be a pharmaceutical composition, a food composition and/or a cosmetic composition of the present invention.
본 발명은 알레르기성 질환의 예방, 개선 또는 치료용 약제의 제조를 위한 6'-하이드록시 저스티시딘-B 또는 이를 포함하는 약학적 조성물의 용도를 제공한다.The present invention provides the use of 6'-hydroxy justicidin-B or a pharmaceutical composition comprising the same for the preparation of a medicament for the prevention, improvement or treatment of allergic diseases.
본 발명은 알레르기성 질환의 예방 또는 개선용 약제의 제조를 위한 6'-하이드록시 저스티시딘-B 또는 이를 포함하는 식품 조성물 또는 화장료 조성물의 용도를 제공한다.The present invention provides a use of 6'-hydroxy justicidin-B or a food composition or cosmetic composition comprising the same for the preparation of a medicament for the prevention or improvement of allergic diseases.
일 실시예에서, 6'-하이드록시 저스티시딘-B는 유기 합성법을 통해 합성한 것일 수 있다.In one embodiment, 6'-hydroxy justicidin-B may be synthesized through organic synthesis.
본 발명의 6'-하이드록시 저스티시딘-B는 Th2의 염증성 사이토카인의 분비를 억제할 수 있으며, 알레르기성 천식 억제 효과 및 아나필락시스 억제효과를 나타내므로, 알레르기성 질환을 효과적으로 예방, 치료 또는 개선할 수 있다.6'-hydroxy justicidin-B of the present invention can inhibit the secretion of Th2 inflammatory cytokines, and exhibits an allergic asthma inhibitory effect and an anaphylactic inhibitory effect, and thus effectively prevents, treats or improves allergic diseases can do.
본 발명에서 상기 알레르기성 질환은 각종 유발 원인에 의하여 야기되는 다양한 질환들을 제한 없이 포함할 수 있다. 예를 들어, 상기 알레르기성 질환은 알레르기성 비염, 알레르기성 천식, 알레르기성 결막염, 아토피 피부염, 알레르기성 장관염, 알레르기성 중이염, 아나필락시스 및 두드러기로 이루어진 군에서 선택된 1종 이상일 수 있다. 본 발명의 실시예들에서, 상기 알레르기성 질환은 알레르기성 호흡기 질환일 수 있다.In the present invention, the allergic disease may include, without limitation, various diseases caused by various triggers. For example, the allergic disease may be one or more selected from the group consisting of allergic rhinitis, allergic asthma, allergic conjunctivitis, atopic dermatitis, allergic enteritis, allergic otitis media, anaphylaxis, and urticaria. In embodiments of the present invention, the allergic disease may be an allergic respiratory disease.
본 명세서에서 용어 "대상체"는, 동물을 말하며, 전형적으로 본 발명의 조성물을 이용한 치료로 유익한 효과를 나타낼 수 있는 포유동물이다. 포유동물은 인간을 포함한 포유동물을 의미하고, 용어 "투여"는 임의의 적절한 방법으로 대상체에게 소정의 물질을 제공하는 것을 의미한다. 본 발명의 유효성분에 대한 치료상 유효 투여량 및 투여 횟수는 원하는 효과에 따라 변화될 것임은 당업자에게 자명하다.As used herein, the term "subject" refers to an animal, typically a mammal capable of exhibiting a beneficial effect by treatment with the composition of the present invention. By mammal is meant mammals, including humans, and the term “administering” means providing a given substance to a subject by any suitable method. It is apparent to those skilled in the art that the therapeutically effective dosage and frequency of administration for the active ingredient of the present invention will vary depending on the desired effect.
본 발명에 있어서, 용어 "인간을 포함한 포유동물"은, 원숭이, 소, 말, 개, 고양이, 토끼, 레트, 마우스 등의 포유동물을 의미하며, 특히 인간을 포함한다. 또한 이와 같은 대상체들에는 알레르기성 질환 증상을 갖거나 이와 같은 증상을 가질 위험이 있는 대상체들이 모두 포함된다.In the present invention, the term "mammal including humans" refers to mammals such as monkeys, cattle, horses, dogs, cats, rabbits, rats, and mice, and in particular includes humans. Also, such subjects include all subjects having or at risk of having symptoms of allergic disease.
본 명세서에서, 용어 "예방"은, 질병, 장애 또는 질환의 발병의 지연을 의미한다. 질병, 장애 또는 질환의 발병이 예정된 기간 동안 지연된 경우 예방은 완전한 것으로 간주될 수 있다.As used herein, the term “prevention” means delaying the onset of a disease, disorder or condition. Prevention may be considered complete if the onset of the disease, disorder or condition is delayed for a predetermined period.
본 명세서에서, 용어 "개선"은, 질병, 장애 또는 질환의 발병을 부분적으로 또는 완전히 경감, 완화, 저해 또는 지연시키며, 중증도를 감소시키거나, 하나 이상의 증상 또는 특징의 발생을 감소시키는 것을 의미한다.As used herein, the term "amelioration" means partially or completely alleviating, alleviating, inhibiting or delaying the onset of a disease, disorder or condition, reducing the severity, or reducing the occurrence of one or more symptoms or features. .
본 명세서에서, 용어 "치료"는, 특정 질병, 장애 및/또는 질환의 발병을 부분적으로 또는 완전히 경감, 개선, 완화, 저해 또는 지연시키며, 중증도를 감소시키거나, 하나 이상의 증상 또는 특징의 발생을 감소시키는 것을 의미한다.As used herein, the term “treatment” refers to partially or completely alleviating, ameliorating, alleviating, inhibiting or delaying the onset of a particular disease, disorder and/or condition, reducing the severity, or preventing the occurrence of one or more symptoms or features. means to reduce
본 발명의 약학적 조성물은 알레르기성 질환을 예방하고 치료하기 위한 통상의 방법에 따라 정제, 환제, 산제, 과립제, 캡슐제, 현탁제, 내용액제, 유제, 시럽제, 에어로졸, 주사용액 등의 형태로 제형화하여 사용될 수 있다. 예를 들어, 본 발명의 약학적 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.The pharmaceutical composition of the present invention is in the form of tablets, pills, powders, granules, capsules, suspensions, internal solutions, emulsions, syrups, aerosols, injection solutions, etc. according to conventional methods for preventing and treating allergic diseases. It can be formulated and used. For example, carriers, excipients and diluents that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, it is prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
본 발명의 조성물은 경구 또는 비경구 투여 (예를 들어, 도포 또는 정맥 내, 피하, 복강 내 주사)할 수 있다.The composition of the present invention may be administered orally or parenterally (eg, application or intravenous, subcutaneous, intraperitoneal injection).
본 명세서에 있어서, 용어 "경구 투여"는 병리학적 증상을 호전하기 위한 약제를 입으로 주입하는 방법이며, 본 명세서에 있어서, 용어 "비경구 투여"는 입으로 투여하는 것을 제외한 피하, 근육내, 정맥, 튜브를 이용한 복강내로 투여하는 방법을 의미한다.As used herein, the term "oral administration" is a method of injecting a drug by mouth for alleviating pathological symptoms, and in this specification, the term "parenteral administration" refers to subcutaneous, intramuscular, It refers to a method of intraperitoneal administration using an intravenous or tube.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 복합 조성물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 탄산칼슘, 수크로스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제도 사용될 수 있다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 포함되며, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면, 습윤제, 감미제, 방향제, 보존제 등이 사용될 수 있다. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the complex composition, for example, starch, calcium carbonate, sucrose, lactose, gelatin, etc. It can be prepared by mixing. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid formulations for oral administration include suspensions, internal solutions, emulsions, syrups, etc., and various excipients, for example, wetting agents, sweeteners, fragrances, preservatives, etc. in addition to commonly used simple diluents such as water and liquid paraffin. can be used
비경구투여를 위한 제제는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제 등을 포함할 수 있다. 비수성용제와 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일 등과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. As the non-aqueous solvent and suspending agent, vegetable oils such as propylene glycol, polyethylene glycol, and olive oil, and injectable esters such as ethyl oleate may be used.
또한, 본 발명의 약학적 조성물은 담체, 부형제 또는 희석제를 추가로 포함할 수 있다. 담체, 부형제 또는 희석제로는 락토즈, 텍스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오즈, 메틸 셀루로오즈, 하이드록시 프로필 메틸 셀룰로오즈, 미정질 셀룰로오즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 에틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 이산화규소 등의 광물 등이 사용될 수 있다.In addition, the pharmaceutical composition of the present invention may further include a carrier, excipient or diluent. Carriers, excipients or diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, hydroxy Minerals such as propyl methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxy benzoate, ethyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate, silicon dioxide, etc. may be used. .
본 발명에 따른 약학적으로 허용가능한 첨가제는 상기 조성물에 대해 0.1~99.9 중량부 포함될 수 있으며, 구체적으로는 0.1~50 중량부를 포함할 수 있으나, 실시예가 이에 한정되는 것은 아니다.The pharmaceutically acceptable additive according to the present invention may be included in an amount of 0.1 to 99.9 parts by weight based on the composition, specifically, 0.1 to 50 parts by weight, but the embodiment is not limited thereto.
본 발명에 따른 약학적 조성물의 투여량은 약학적으로 유효한 양이어야 한다. "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 예방 또는 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 제제화 방법, 환자의 상태 및 체중, 환자의 성별, 연령, 질환의 정도, 약물형태, 투여경로 및 기간, 배설 속도, 반응 감응성 등과 같은 요인들에 따라 당업자에 의해 다양하게 선택될 수 있다. 유효량은 당업자에게 인식되어 있듯이 처리의 경로, 부형제의 사용 및 다른 약제와 함께 사용할 수 있는 가능성에 따라 변할 수 있다.The dosage of the pharmaceutical composition according to the present invention should be a pharmaceutically effective amount. "Pharmaceutically effective amount" means an amount sufficient to prevent or treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level includes the formulation method, the patient's condition and weight, the patient's sex, and age. , can be variously selected by those skilled in the art according to factors such as the degree of disease, drug form, administration route and duration, excretion rate, reaction sensitivity, and the like. An effective amount will vary depending on the route of treatment, the use of excipients, and the potential for use with other agents, as will be appreciated by those skilled in the art.
알레르기성 질환을 예방 또는 치료하는데 유효한 양은 단일 또는 다중 용량으로, 단독 또는 하나 또는 그 이상의 다른 조성물들(다른 알레르기성 질환 치료제 등)과 조합으로, 대상체에서 원하는 성과 또는 객관적이거나 또는 주관적인 이점을 제공하는 양을 의미할 수 있다.An amount effective to prevent or treat an allergic disease is administered in single or multiple doses, alone or in combination with one or more other compositions (such as other therapeutic agents for allergic diseases), which provides the desired performance or objective or subjective benefit in the subject. It can mean quantity.
본 발명에 따른 약학적 조성물의 투여량 또는 복용량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도에 따라 그 범위가 다양하나, 성인 기준으로 0.001 mg/kg 내지 1000 mg/kg을 1회 내지 수회에 나누어 복용될 수 있다.The dosage or dosage of the pharmaceutical composition according to the present invention varies depending on the patient's weight, age, sex, health status, diet, administration time, administration method, excretion rate, and severity of disease, but is 0.001 on an adult basis mg/kg to 1000 mg/kg may be administered in one to several divided doses.
또한 본 발명은 발명의 또 다른 양태로 6'-하이드록시 저스티시딘-B를 유효성분으로 포함하는 알레르기성 질환의 예방 또는 개선용 화장료 조성물을 제공한다. In another aspect of the present invention, there is provided a cosmetic composition for preventing or improving allergic diseases comprising 6'-hydroxy justicidin-B as an active ingredient.
본 발명에서, 상기 화장료 조성물은 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 파우더, 바디로션, 바디크림, 바디오일, 바디에센스, 메이크업 베이스, 파운데이션, 염모제, 샴푸, 린스 및 바디 세정제로 이루어지는 군으로부터 선택되는 제형일 수 있다.In the present invention, the cosmetic composition is a softening lotion, astringent lotion, nutrient lotion, nutrition cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, It may be a formulation selected from the group consisting of body oil, body essence, makeup base, foundation, hair dye, shampoo, conditioner and body cleanser.
본 발명의 화장료 조성물은 상기 6'-하이드록시 저스티시딘-B를 사용하여 통상의 화장료 제조방법에 따라, 다양한 형태로 제조될 수 있으며, 화장료 조성물 분야에서 통상적으로 사용되는 안정화제, 용해화제, 비타민, 안료, 및 향료와 같은 통상적인 보조제를 포함할 수 있다. The cosmetic composition of the present invention can be prepared in various forms according to a conventional cosmetic preparation method using the 6'-hydroxy justicidin-B, and a stabilizer, solubilizer, It may contain conventional adjuvants such as vitamins, pigments, and flavorings.
또한, 화장료 조성물이 상기 6'-하이드록시 저스티시딘-B를 함유하는 향장 제품, 샴푸, 헤어로션, 헤어크림, 헤어젤 등의 형태로 제조될 경우, 통상의 클렌징액, 수렴액 및 보습액으로 희석하여 사용될 수 있다. In addition, when the cosmetic composition is prepared in the form of cosmetic products containing the 6'-hydroxy justicidin-B, shampoo, hair lotion, hair cream, hair gel, etc. It can be used after dilution.
본 발명의 화장료 조성물은 특히 화장수, 로션, 크림, 에센스 형태로 제조되는 것이 바람직하다. The cosmetic composition of the present invention is particularly preferably prepared in the form of a lotion, lotion, cream, or essence.
본 발명의 화장료 조성물에서 6'-하이드록시 저스티시딘-B는 총 액상 중량에 대하여 0.1중량%~10중량%의 양으로 화장료에 첨가될 수 있고, 또한 화장료 조성물의 총 건조중량에 대하여 0.001~5중량%, 바람직하게는 0.01~3중량%의 양으로 화장료에 첨가될 수 있다.In the cosmetic composition of the present invention, 6'-hydroxy justicidin-B may be added to the cosmetic in an amount of 0.1% to 10% by weight based on the total liquid weight, and 0.001 to about the total dry weight of the cosmetic composition. It may be added to the cosmetic in an amount of 5% by weight, preferably 0.01 to 3% by weight.
이상 본 명세서에 기재된 수치 값은 달리 명시되어 있지 않은 한 균등범위까지 포함하는 것으로 해석되어야 한다.Numerical values described in the present specification above should be interpreted as including equivalent ranges unless otherwise specified.
본 발명의 용도, 조성물 및 예방, 개선 및/또는 치료 방법 각각에서 언급된 사항은 서로 모순되지 않는 한 동일한 내용이 적용될 수 있다.Items mentioned in each of the uses, compositions, and prevention, improvement and/or treatment methods of the present invention may be applied as long as they do not contradict each other.
본 발명의 6'-하이드록시 저스티시딘-B는 알레르기성 질환과 관련된 Th2 세포로의 분화를 우수하게 억제하였으며, 알레르기 천식 Balb/c 마우스 모델에서 낮은 농도를 투여한 경우에도 천식 질환을 억제에 있어서 우수한 효과를 나타낸다. 따라서, 본 발명에 따른 6'-하이드록시 저스티시딘-B를 포함하는 약학적 조성물, 식품 조성물 및 화장료 조성물은 알레르기성 질환의 예방, 치료 또는 개선제로 널리 활용될 수 있다. The 6'-hydroxy justicidin-B of the present invention excellently inhibited the differentiation of Th2 cells related to allergic diseases, and was effective in inhibiting asthma diseases even when administered at low concentrations in the Balb/c mouse model of allergic asthma. shows an excellent effect. Accordingly, the pharmaceutical composition, food composition, and cosmetic composition comprising 6'-hydroxy justicidin-B according to the present invention can be widely used as an agent for preventing, treating or improving allergic diseases.
도 1은 본 발명에 따른 6'-하이드록시 저스티시딘-B의 화학적 구조를 나타낸 도이다. 1 is a diagram showing the chemical structure of 6'-hydroxy justicidin-B according to the present invention.
이하, 본 발명의 이해를 돕기 위하여 바람직한 제조예, 실시예 및 제제예를 제시한다. 그러나 하기의 제조예, 실시예 및 제제예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 제조예, 실시예 및 제제예에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred preparation examples, examples and preparation examples are presented to help the understanding of the present invention. However, the following Preparation Examples, Examples and Formulation Examples are only provided for easier understanding of the present invention, and the content of the present invention is not limited by the Preparation Examples, Examples and Formulation Examples.
제조예 1: 유기 합성법을 통한 6'-하이드록시 저스티시딘-B의 제조Preparation Example 1: Preparation of 6'-hydroxy justicidin-B through organic synthesis
6'-하이드록시 저스티시딘-B는 아래의 공정을 통해 합성하였다. 6'-하이드록시 저스티시딘-B의 구조는 도 1에 도시된 것과 같다.6'-hydroxy justicidin-B was synthesized through the following process. The structure of 6'-hydroxy justicidin-B is as shown in FIG. 1 .
Figure PCTKR2021007775-appb-img-000001
Figure PCTKR2021007775-appb-img-000001
공정 1: 6,7-디메톡시-3-옥소-1,3-디히드로나프토[2,3-c]퓨란-4-일 트리플루오로메탄설포네이트 (3.0g, 7.65mmol)을 디옥산(90ml)용매에 녹인 후, 5-메톡시메톡시-6-(4,4,5,5,-테트라메틸-[1,3,2]다이옥사보로란-2-일)-벤조[1,3]디옥솔 (2.83g, 9.18mmol), [1,1'-비스(디 페닐 포스피노) 페로센]디클로로 팔라듐(II) (1.12g, 1.53mmol) 및 수산화리튬 1수화물(642mg, 15.3mmol)을 질소대기하에서 순차적으로 부가하였다. 온도를 60℃까지 올린 뒤 4시간 동안 반응시켰다. 상온으로 냉각 후에 물을 가하여 반응을 종결시키고 디클로로메탄으로 추출하였다. 유기층을 무수 Na2SO4로 건조시키고, 여과 및 농축시켰다. 잔사를 실리카겔 컬럼 크로마토그래피로 정제하여 표제화합물 6,7-디메톡시-9-(6-메톡시메톡시-벤조[1,3]디옥솔-5-일)-3H-나프토[2,3-c]퓨란-1-온 (9g, 21.2mmol)을 얻었다.Step 1: 6,7-dimethoxy-3-oxo-1,3-dihydronaphtho [2,3-c] furan-4-yl trifluoromethanesulfonate (3.0 g, 7.65 mmol) was mixed with dioxane (90ml) After dissolving in a solvent, 5-methoxymethoxy-6-(4,4,5,5,-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzo[1 ,3]dioxole (2.83g, 9.18mmol), [1,1'-bis(diphenyl phosphino)ferrocene]dichloropalladium(II) (1.12g, 1.53mmol) and lithium hydroxide monohydrate (642mg, 15.3mmol) ) were sequentially added under a nitrogen atmosphere. After raising the temperature to 60 °C, the reaction was carried out for 4 hours. After cooling to room temperature, water was added to terminate the reaction, and extraction was performed with dichloromethane. The organic layer was dried over anhydrous Na 2 SO 4 , filtered and concentrated. The residue was purified by silica gel column chromatography, and the title compound 6,7-dimethoxy-9-(6-methoxymethoxy-benzo[1,3]dioxol-5-yl)-3H-naphtho[2,3] -c] furan-1-one (9 g, 21.2 mmol) was obtained.
1H NMR: (DMSO-d 6, 400 MHz) δ 7.92 (s, 1H), 7.48 (s, 1H), 6.95 (s, 1H), 6.87 (s, 1H), 6.73 (s, 1H), 6.08 (d, 2H, J = 2.8 Hz), 5.38 - 5.49 (m, 2H), 4.90 (d, 1H, J = 6.8 Hz), 4.81 (d, 1H, J = 6.8Hz), 3.93 (s, 3H), 3.65 (s, 3H), 2.93 (s, 3H). 1 H NMR: (DMSO- d 6 , 400 MHz) δ 7.92 (s, 1H), 7.48 (s, 1H), 6.95 (s, 1H), 6.87 (s, 1H), 6.73 (s, 1H), 6.08 (d, 2H, J = 2.8 Hz), 5.38 - 5.49 (m, 2H), 4.90 (d, 1H, J = 6.8 Hz), 4.81 (d, 1H, J = 6.8 Hz), 3.93 (s, 3H) , 3.65 (s, 3H), 2.93 (s, 3H).
공정 2: 6,7-디메톡시-9-(6-메톡시메톡시-벤조[1,3]디옥솔-5-일)-3H-나프토[2,3-c]퓨란-1-온 (8g, 18.9mmol)을 에탄올(80ml)에 녹이고, 12M HCl 44ml를 적가하여 50℃에서 12시간 반응시켰다. 반응이 종결된 후에 물 100ml를 가하고, 디클로로메탄(200ml, 100ml, 50ml)으로 추출하였다. 얻어진 유기층을 물(150ml), brine(100ml)를 사용하여 씻어주고, 무수 Na2SO4로 건조시킨 후에 여과하여 농축시켰다. 잔사를 실리카겔 컬럼 크로마토그래피로 정제하여 표제화합물 9-(6-하이드록시-벤조[1,3]다이옥솔-5-일)-6,7-디메톡시-3H-나프토[2,3-c]퓨란-1-온 (6'-HJB, 5.20g, 13.7mmol, 72.5%)을 얻었다.Step 2: 6,7-dimethoxy-9-(6-methoxymethoxy-benzo[1,3]dioxol-5-yl)-3H-naphtho[2,3-c]furan-1-one (8g, 18.9mmol) was dissolved in ethanol (80ml), and 44ml of 12M HCl was added dropwise, followed by reaction at 50°C for 12 hours. After the reaction was completed, 100 ml of water was added, and the mixture was extracted with dichloromethane (200 ml, 100 ml, 50 ml). The obtained organic layer was washed with water (150ml) and brine (100ml), dried over anhydrous Na 2 SO 4 , filtered and concentrated. The residue was purified by silica gel column chromatography, and the title compound 9-(6-hydroxy-benzo[1,3]dioxol-5-yl)-6,7-dimethoxy-3H-naphtho[2,3-c ] furan-1-one (6'-HJB, 5.20 g, 13.7 mmol, 72.5%) was obtained.
1H NMR: (DMSO-d 6, 400 MHz) δ 9.01 (s, 1H), 7.88 (s, 1H), 7.46 (s, 1H), 6.95 (s, 1H), 6.63 (s, 1H), 6.57 (s, 1H), 6.00 (d, 2H, J = 2.00 Hz), 5.41 (s, 2H), 3.93 (s, 3H), 3.66 (s, 3H). 6'-하이드록시 저스티시딘-B의 순도는 98.76%이었다. 1 H NMR: (DMSO- d 6 , 400 MHz) δ 9.01 (s, 1H), 7.88 (s, 1H), 7.46 (s, 1H), 6.95 (s, 1H), 6.63 (s, 1H), 6.57 (s, 1H), 6.00 (d, 2H, J = 2.00 Hz), 5.41 (s, 2H), 3.93 (s, 3H), 3.66 (s, 3H). The purity of 6'-hydroxy justicidin-B was 98.76%.
실시예 1. CD4 T세포에서 Th2 세포로의 분화 억제 효과 비교 실험Example 1. Comparative experiment on the effect of inhibiting differentiation from CD4 T cells to Th2 cells
6'-하이드록시 저스티시딘-B의 Th2 세포로의 분화 억제 효과를 확인하기 위해 하기와 같이 실험을 진행하였다. Balb/c 마우스로부터 분리한 비장(spleen)을 이용하여 비장 세포(splenocyte)를 분리하였고, CD4 T 세포 선택적 분리 키트(CD4 T cell isolation kit, Miltenyi Biotec)를 이용하여 비장세포로부터 CD4 T세포를 분리하였다. 분리한 CD4 T 세포는 5% 태아 송아지 혈청(Fetal bovine serum, FBS)과 항생제(페니실린 100 U/mL, 스트렙토마이신 100 μg/mL) 및 50 μM 2-머캅토에탄올이 포함된 RPMI 배지에 1X106 세포/mL 농도로 희석한 후, anti-CD3/anti-CD28 항체가 코팅된 48 웰 플레이트에 500 ㎕/well 씩 분주하였고, 37℃ 5 % CO2 배양기에 넣어 48시간 동안 배양하였다. 이때 CD4 T세포를 Th0 세포로 유도 및 유지하기 위해 20 ng/mL의 인터류킨-2(IL-2)를 추가로 처리하였고, Th0 세포를 Th2 세포로 유도하기 위해 20 ng/mL의 인터류킨-2(IL-2), 100 ng/mL의 인터류킨-4(IL-4), 10 μg/mL의 인터페론-감마 항체 (anti-IFNγ antibody), 10 μg/mL의 인터류킨-12 항체 (anti-IL12 antibody)를 추가하였으며, 이때 제조예 1에서 제조된 6'-하이드록시 저스티시딘-B를 처리하였다. 24 웰 플레이트의 배지는 Th2 염증성 사이토카인인 인터류킨-5(IL-5) 분비 정도를 측정하는데 사용하였다. 먼저 Th2에 의해 분비되는 사이토카인들을 측정하기 위해 24 웰 플레이트에 있는 배지를 수집하여 800xg에서 5분간 원심분리를 통해 상층액만을 분리하였으며, 상층액 중 웰당 100 ㎕씩을 IL-5 효소결합 면역흡착분석법(ELISA, 고마바이오텍) 실험에 이용하여 이들 사이토카인의 분비 정도를 측정하였다. 약물에 의한 IL-5의 분비 억제 정도는 다음 [식 1]를 이용하여 계산하였다. In order to confirm the inhibitory effect of 6'-hydroxy justicidin-B on differentiation into Th2 cells, an experiment was conducted as follows. Splenocytes were isolated using spleen isolated from Balb/c mice, and CD4 T cells were isolated from splenocytes using a CD4 T cell isolation kit (Miltenyi Biotec). did The isolated CD4 T cells were 1X10 6 in RPMI medium containing 5% fetal bovine serum (FBS), antibiotics (penicillin 100 U/mL, streptomycin 100 μg/mL), and 50 μM 2-mercaptoethanol. After dilution to a cell/mL concentration, 500 μl/well was dispensed into a 48-well plate coated with anti-CD3/anti-CD28 antibody, and incubated for 48 hours at 37° C. 5% CO 2 in an incubator. At this time, to induce and maintain CD4 T cells into Th0 cells, 20 ng/mL of interleukin-2 (IL-2) was additionally treated, and to induce Th0 cells into Th2 cells, 20 ng/mL of interleukin-2 ( IL-2), 100 ng/mL of interleukin-4 (IL-4), 10 μg/mL of interferon-gamma antibody (anti-IFNγ antibody), 10 μg/mL of interleukin-12 antibody (anti-IL12 antibody) was added, and at this time, 6'-hydroxy justicidin-B prepared in Preparation Example 1 was treated. The medium of the 24-well plate was used to measure the secretion level of interleukin-5 (IL-5), a Th2 inflammatory cytokine. First, in order to measure cytokines secreted by Th2, the medium in a 24-well plate was collected, and only the supernatant was separated by centrifugation at 800xg for 5 minutes. (ELISA, Goma Biotech) The degree of secretion of these cytokines was measured using the experiment. The degree of inhibition of IL-5 secretion by the drug was calculated using the following [Equation 1].
[식 1][Equation 1]
Figure PCTKR2021007775-appb-img-000002
Figure PCTKR2021007775-appb-img-000002
시험군test group 농도 (nM)Concentration (nM) IL-5 억제능 (%)IL-5 inhibitory ability (%)
6'-하이드록시 저스티시딘-B6'-hydroxy justicidin-B 0.10.1 44.9±0.9044.9±0.90
0.50.5 44.9±2.7144.9±2.71
1One 50.1±1.0950.1±1.09
1010 57.2±1.2957.2±1.29
위 표 1의 기재를 참조하면 6'-하이드록시 저스티시딘-B의 우수한 인터류킨-5 분비 억제효과가 확인된다. 특히, 6'-하이드록시 저스티시딘-B는 낮은 농도로도 우수한 IL-5 분비 억제 효과가 달성됨이 확인된다. 이로부터, 6'-하이드록시 저스티시딘-B의 Th2 세포로의 우수한 분화 억제 효과 및 6'-하이드록시 저스티시딘-B의 우수한 알레르기성 질환에 대한 예방, 개선, 또는 치료 효과를 확인하였다.Referring to Table 1 above, the excellent inhibitory effect on interleukin-5 secretion of 6'-hydroxy justicidin-B is confirmed. In particular, it is confirmed that 6'-hydroxy justicidin-B achieves an excellent IL-5 secretion inhibitory effect even at a low concentration. From this, the excellent inhibitory effect of 6'-hydroxy justicidin-B into Th2 cells and the excellent prevention, improvement, or therapeutic effect of 6'-hydroxy justicidin-B on allergic diseases were confirmed. .
실시예 2. OVA 천식 Balb/c 마우스모델에서의 약효 평가Example 2. Efficacy evaluation in OVA asthma Balb/c mouse model
6주령 Balb/c 마우스를 구입한 후 1주일간 순화시키고, 순화 일주일 후부터 0, 14일에 0.1% 난백알부민(OVA 1mg/mL, Al(OH)3 20mg/mL)을 제조하여 100 ㎕/mouse 양을 복강 주사하여 전신 감작시켰다. 최종 전신감작 후 일주일 뒤(21일째)부터 매일 10일간 시험 약물들을 경구투여하고, 한 시간 뒤 네블라이져(PARI Boy SX, 독일 GmbH사)를 이용하여 0.2% 난백알부민 용액을 분무하여 1시간 동안 흡입시켰다. 최종 감작(30일째) 후 5시간 뒤에 부검하여 혈액 및 폐세척액을 확보하였으며, 폐조직은 10% 중성 포르말린에 고정하였다. 그 후 혈액 및 폐세척액은 IgE 및 Th2 사이토카인, 면역세포측정에 사용하였고, 폐 조직은 절단하여 슬라이드로 제작하고, H&E 염색을 실시하여 조직을 관찰하였다. 폐조직의 관찰은 현미경 400배의 상을 촬영하고, 촬영된 조직의 폐상피(Epithelium) 두께를 Image-pro Plus 6.0 프로그램을 사용하여 측정하였다. 그 결과를 표 2 및 표 3에 나타냈고, 억제능은 실시예 1에서 전술한 [식 1]을 이용하여 계산하였다. After purchase, 6-week-old Balb/c mice were acclimatized for 1 week, and 0.1% egg white albumin (OVA 1 mg/mL, Al(OH) 3 20 mg/mL) was prepared on days 0 and 14 from one week after acclimatization, in an amount of 100 μl/mouse. systemic sensitization by intraperitoneal injection. After the final systemic sensitization, the test drugs were orally administered for 10 days every day from one week after the final systemic sensitization, and an hour later, 0.2% egg white albumin solution was sprayed using a nebulizer (PARI Boy SX, Germany GmbH) and inhaled for 1 hour. . Blood and lung lavage were obtained by autopsy 5 hours after the final sensitization (day 30), and lung tissue was fixed in 10% neutral formalin. After that, blood and lung lavage were used for IgE and Th2 cytokines and immune cytometry, and the lung tissue was cut to make a slide, and the tissue was observed by performing H&E staining. Observation of lung tissue was photographed at 400 times the microscope, and the thickness of the lung epithelium of the photographed tissue was measured using the Image-pro Plus 6.0 program. The results are shown in Tables 2 and 3, and the inhibitory ability was calculated using [Equation 1] described above in Example 1.
시험군 (n=5)Test group (n=5) 약물 농도
(mg/kg)drug concentration
(mg/kg) 		혈청
(억제능 %,
Mean±SE)serum
(inhibition %,
Mean±SE) 		폐세척액 (억제능 %, Mean±SE)Lung lavage fluid (inhibitory %, Mean±SE)
IgEIgE IgEIgE IL-5IL-5 호산구eosinophils 전체
세포수all
number of cells
6’-하이드록시 저스티시딘-B6'-hydroxy justicidin-B 0.10.1 66.9±12.566.9±12.5 70.8±7.570.8±7.5 68.2±6.368.2±6.3 84.2±5.184.2±5.1 87.8±7.287.8±7.2
몬테루카스트
(양성대조군)monterukast
(positive control group) 		1010 -5.6±20.1-5.6±20.1 60.2±4.260.2±4.2 37.0±16.737.0±16.7 43.7±13.943.7±13.9 12.7±15.212.7±15.2
시험군 (n=5)Test group (n=5) 약물 농도 (mg/kg)Drug Concentration (mg/kg) 폐상피 두께
(억제능 %, Mean±SE)lung epithelium thickness
(Inhibition %, Mean±SE)
6’-하이드록시
저스티시딘-B6'-hydroxy
Justicidin-B 		0.10.1 44.2±6.444.2±6.4
몬테루카스트
(양성대조군)monterukast
(positive control group) 		1010 -25.6±55.7-25.6±55.7
표 2에 나타난 바와 같이 6'-하이드록시 저스티시딘-B를 0.1mg/kg을 투여한 경우, 알레르기성 천식 질환과 관련된 여러 지표들이 6'-하이드록시 저스티시딘-B의 농도 보다 100배 높은 10mg/kg의 몬테루카스트를 투여한 경우 보다 현저히 감소하는 것이 확인되며, 표 3에 나타난 바와 같이 폐상피 두께 또한 현저히 감소함이 확인된다.As shown in Table 2, when 0.1 mg/kg of 6'-hydroxy justicidin-B was administered, various indicators related to allergic asthma disease were 100 times higher than the concentration of 6'-hydroxy justicidin-B. It was confirmed that the montelukast at a high dose of 10 mg/kg was significantly reduced, and as shown in Table 3, the lung epithelial thickness was also significantly reduced.
이를 통해, 6'-하이드록시 저스티시틴-B의 알레르기성 천식 질환에 대한 우수한 예방, 개선 또는 치료 효과가 확인된다.Through this, the excellent preventive, ameliorating or therapeutic effect of 6'-hydroxy justcitin-B for allergic asthma is confirmed.
실시예 3. 아낙필락시스 ICR 마우스모델에서의 약효 평가Example 3. Efficacy evaluation in anaphylaxis ICR mouse model
6주령 ICR 마우스는 체중에 의거하여 군 분리하였으며, Compound 48/80 (Sigma #C2313)을 16mg/kg 농도로 복강투여하여 아낙필락시스를 유도하였다. 상기 6'-하이드록시 저스티시딘-B 및 양성대조군 DSCG (Cromolyn sodium, Sigma #C0399) 250 mg/kg을 각각 아낙필락시스 유도 1시간 전에 복강 투여하였으며, 아낙필락시스 유도 후 30분간 사망률 (Mortality)를 관찰하였고, 그 결과를 표 4에 나타냈다. 아낙필락시스 억제능은 하기 [식 2]를 이용하여 계산하였다.6-week-old ICR mice were grouped based on body weight, and anaphylaxis was induced by intraperitoneal administration of Compound 48/80 (Sigma #C2313) at a concentration of 16 mg/kg. The 6'-hydroxy justicidin-B and the positive control group DSCG (Cromolyn sodium, Sigma #C0399) 250 mg/kg were administered intraperitoneally 1 hour before anaphylaxis induction, respectively, and mortality (mortality) for 30 minutes after anaphylaxis induction. ) was observed, and the results are shown in Table 4. Anaphylaxis inhibitory ability was calculated using the following [Equation 2].
[식 2][Equation 2]
Figure PCTKR2021007775-appb-img-000003
Figure PCTKR2021007775-appb-img-000003
시험군 (n=10)Test group (n=10) 약물 농도 (mg/kg)Drug Concentration (mg/kg) 아낙필락시스 억제능 (%)Anaphylaxis inhibitory ability (%)
6’-하이드록시
저스티시딘-B6'-hydroxy
Justicidin-B 		0.10.1 4343
DSCG (양성대조군)DSCG (positive control) 200200 1414
표 4에 나타난 바와 같이, 전신성 알레르기성 질환인 아낙필락시스에 대한 동물 실험에서, DSCG를 투여한 경우의 아낙필락시스 사망률 감소율보다 DSCG의 2000분의 1의 농도로 6'-하이드록시 저스티시딘-B를 투여한 경우의 사망률 감소 효과가 더 크게 나타났다. 이를 통해, 6'-하이드록시 저스티시딘-B의 우수한 알레르기성 질환의 예방, 개선 또는 치료 효과가 확인된다.As shown in Table 4, in an animal experiment on anaphylaxis, a systemic allergic disease, 6'-hydroxy justicidine at a concentration of 1/2000 of DSCG compared to the decrease in anaphylaxis mortality when DSCG was administered. -B administration had a greater reduction in mortality. Through this, the excellent prevention, improvement or therapeutic effect of 6'-hydroxy justicidin-B for allergic diseases is confirmed.
제제예 1: 의약품의 제조Formulation Example 1: Preparation of pharmaceuticals
1-1. 산제의 제조1-1. Preparation of powders
6'-하이드록시 저스티시딘-B 100mg6'-hydroxy justicidin-B 100mg
유당 100mgLactose 100mg
탈크 10mgtalc 10mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight bag to prepare a powder.
1-2. 정제의 제조1-2. manufacture of tablets
6'-하이드록시 저스티시딘-B 100mg6'-hydroxy justicidin-B 100mg
옥수수전분 100mgCorn Starch 100mg
유당 100mgLactose 100mg
스테아린산 마그네슘 2mg2mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above ingredients, tablets are prepared by tableting according to a conventional manufacturing method of tablets.
1-3. 캡슐제의 제조1-3. manufacture of capsules
6'-하이드록시 저스티시딘-B 100mg6'-hydroxy justicidin-B 100mg
옥수수전분 100mgCorn Starch 100mg
유당 100mgLactose 100mg
스테아린산 마그네슘 2mg2mg magnesium stearate
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled in a gelatin capsule to prepare a capsule.
1-4. 주사제의 제조1-4. manufacture of injections
6'-하이드록시 저스티시딘-B 100mg6'-hydroxy justicidin-B 100mg
주사용 멸균 증류수 적량Appropriate amount of sterile distilled water for injection
pH 조절제 적량Appropriate amount of pH adjuster
통상의 주사제의 제조방법에 따라 1 앰플당(2ml) 상기의 성분 함량으로 제조한다.According to a conventional method for preparing injections, the content of the above ingredients per 1 ampoule (2 ml) is prepared.
1-5. 액제의 제조1-5. Preparation of liquids
6'-하이드록시 저스티시딘-B 100mg6'-hydroxy justicidin-B 100mg
설탕 20g20 g sugar
이성화당 20gIsomerized sugar 20g
레몬향 적량Lemon flavored amount
정제수를 가하여 전체 1,000 ml로 맞춘다. 통상의 액제의 제조방법에 따라 상기의 성분을 혼합한 다음, 갈색병에 충전하고 멸균시켜 액제를 제조한다.Add purified water to make the total volume of 1,000 ml. After mixing the above ingredients according to a conventional liquid preparation method, it is filled in a brown bottle and sterilized to prepare a liquid preparation.
1-6. 흡입제의 제조1-6. manufacture of inhalants
6'-하이드록시 저스티시딘-B 100mg6'-hydroxy justicidin-B 100mg
1,1,1,2-테트라플루오르에탄 15g15 g of 1,1,1,2-tetrafluoroethane
무수에탄올 1.5g1.5 g of absolute ethanol
구연산(무수물) 0.05mgCitric acid (anhydrous) 0.05 mg
폴리에틸렌글리콜 500mgPolyethylene glycol 500mg
통상의 흡입제의 제조방법에 따라, 상기의 성분을 혼합하여 용기에 충전한다.According to a conventional method for preparing inhalants, the above ingredients are mixed and filled in a container.
제제예 2: 식품의 제조Formulation Example 2: Preparation of food
6'-하이드록시 저스티시딘-B 100mg6'-hydroxy justicidin-B 100mg
비타민 혼합물 적량appropriate amount of vitamin mixture
비타민 A 아세테이트 70 ㎍70 μg vitamin A acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎Vitamin B1 0.13 mg
비타민 B2 0.15 ㎎Vitamin B2 0.15 mg
비타민 B6 0.5 ㎎Vitamin B6 0.5 mg
비타민 B12 0.2 ㎍0.2 μg of vitamin B12
비타민 C 10 ㎎Vitamin C 10 mg
비오틴 10 ㎍Biotin 10 μg
니코틴산아미드 1.7 ㎎Nicotinamide 1.7 mg
엽산 50 ㎍50 μg of folic acid
판토텐산 칼슘 0.5 ㎎Calcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture appropriate amount
황산제1철 1.75 ㎎Ferrous sulfate 1.75 mg
산화아연 0.82 ㎎Zinc oxide 0.82 mg
제1인산칼륨 15 ㎎Potassium monophosphate 15 mg
제2인산칼슘 55 ㎎Dibasic calcium phosphate 55 mg
구연산칼륨 90 ㎎Potassium citrate 90 mg
탄산칼슘 100 ㎎Calcium carbonate 100 mg
염화마그네슘 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 건강기능식품에 적합한 성분을 바람직한 실시예로서 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강기능식품 제조방법에 따라 상기의 성분을 혼합한 다음, 통상의 방법에 따라 건강기능식품 조성물 제조(예, 영양캔디 등)에 사용할 수 있다.The composition ratio of the above vitamin and mineral mixture is mixed composition with ingredients suitable for health functional food as a preferred embodiment, but the mixing ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health functional food manufacturing method. Next, according to a conventional method, it can be used for manufacturing a health functional food composition (eg, nutritional candy, etc.).
제제예 3: 음료의 제조Formulation Example 3: Preparation of beverage
6'-하이드록시 저스티시딘-B 100mg6'-hydroxy justicidin-B 100mg
구연산 1000 ㎎citric acid 1000 mg
올리고당 100 g100 g of oligosaccharides
매실농축액 2 g2 g of plum concentrate
타우린 1 g1 g taurine
정제수를 가하여 전체 900 ㎖Total 900 ml by adding purified water
통상의 건강기능성 음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강기능성 음료 조성물 제조에 사용한다. 상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.After mixing the above ingredients according to the usual health functional beverage manufacturing method, after stirring and heating at 85°C for about 1 hour, the resulting solution is filtered and acquired in a sterilized 2L container, sealed and sterilized, then refrigerated. It is used to prepare the health functional beverage composition of the present invention. Although the composition ratio is prepared by mixing ingredients suitable for relatively favorite beverages in a preferred embodiment, the blending ratio may be arbitrarily modified according to regional and national preferences such as demand class, demanding country, and use purpose.
제제예 4: 화장료의 제조Formulation Example 4: Preparation of cosmetics
6'-하이드록시 저스티시딘-B 100mg6'-hydroxy justicidin-B 100mg
글리세린 3.0 ㎎Glycerin 3.0 mg
하이드로제네이티드 레시친 1.0 ㎎Hydrogenated Lecithin 1.0 mg
세토스테아릴알콜 2.0 mgcetostearyl alcohol 2.0 mg
폴리소르베이트 60 1.5 mgPolysorbate 60 1.5 mg
항산화제 0.3 mgAntioxidant 0.3 mg
방부제 적량Appropriate amount of preservative
정제수 적량Purified water appropriate amount
통상의 화장료 제조방법에 따라, 상기의 성분을 혼합하여 화장료를 제조하였다.According to a conventional cosmetic preparation method, the above ingredients were mixed to prepare a cosmetic.

Claims (10)

  1. 6'-하이드록시 저스티시딘-B를 유효성분으로 포함하는 알레르기성 질환의 예방 또는 치료용 약학적 조성물.A pharmaceutical composition for preventing or treating allergic diseases comprising 6'-hydroxy justicidin-B as an active ingredient.
  2. 제1항에 있어서,According to claim 1,
    상기 알레르기성 질환은 알레르기성 비염, 알레르기성 천식, 알레르기성 결막염, 아토피 피부염, 알레르기성 장관염, 알레르기성 중이염, 아나필락시스 및 두드러기로 이루어진 군에서 선택된 어느 하나 이상인 알레르기성 질환의 예방 또는 치료용 약학적 조성물.The allergic disease is a pharmaceutical for preventing or treating any one or more allergic diseases selected from the group consisting of allergic rhinitis, allergic asthma, allergic conjunctivitis, atopic dermatitis, allergic enteritis, allergic otitis media, anaphylaxis and urticaria. composition.
  3. 제1항에 있어서,According to claim 1,
    상기 알레르기성 질환은 알레르기성 호흡기 질환인 알레르기성 질환의 예방 또는 치료용 약학적 조성물.The allergic disease is an allergic respiratory disease, a pharmaceutical composition for preventing or treating an allergic disease.
  4. 제1항에 있어서,According to claim 1,
    상기 약학적 조성물은 6'-하이드록시 저스티시딘-B를 0.1mg/g 내지 200mg/g 포함하는 것인 알레르기성 질환의 예방 또는 치료용 약학적 조성물.The pharmaceutical composition is a pharmaceutical composition for the prevention or treatment of allergic diseases comprising 6'-hydroxy justicidin-B 0.1 mg/g to 200 mg/g.
  5. 6'-하이드록시 저스티시딘-B를 유효성분으로 포함하는 알레르기성 질환의 예방 또는 개선용 식품 조성물.A food composition for preventing or improving allergic diseases comprising 6'-hydroxy justicidin-B as an active ingredient.
  6. 제5항에 있어서,6. The method of claim 5,
    상기 식품은 건강기능식품인 알레르기성 질환의 예방 또는 개선용 식품 조성물.The food is a health functional food, a food composition for the prevention or improvement of allergic diseases.
  7. 6'-하이드록시 저스티시딘-B를 유효성분으로 포함하는 알레르기성 질환의 예방 또는 개선용 화장료 조성물.A cosmetic composition for preventing or improving allergic diseases comprising 6'-hydroxy justicidin-B as an active ingredient.
  8. 6'-하이드록시 저스티시딘-B 또는 이를 포함하는 조성물을 이를 필요로 하는 대상체에게 투여함을 포함하는 알레르기성 질환을 예방, 개선 또는 치료하는 방법.A method for preventing, ameliorating or treating an allergic disease, comprising administering to a subject in need thereof 6'-hydroxy justicidin-B or a composition comprising the same.
  9. 알레르기성 질환의 예방, 개선 또는 치료를 위한 6'-하이드록시 저스티시딘-B 또는 이를 포함하는 조성물의 용도.Use of 6'-hydroxy justicidin-B or a composition comprising the same for the prevention, improvement or treatment of an allergic disease.
  10. 알레르기성 질환의 예방, 개선 또는 치료용 약제의 제조를 위한 6'-하이드록시 저스티시딘-B 또는 이를 포함하는 조성물의 용도.Use of 6'-hydroxy justicidin-B or a composition comprising the same for the manufacture of a medicament for the prevention, improvement or treatment of an allergic disease.
PCT/KR2021/007775 2020-06-22 2021-06-21 Composition comprising 6'-hydroxy justcidin-b, for preventing, ameliorating or treating allergic diseases WO2021261870A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2020-0075763 2020-06-22
KR20200075763 2020-06-22

Publications (1)

Publication Number Publication Date
WO2021261870A1 true WO2021261870A1 (en) 2021-12-30

Family

ID=79176943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/007775 WO2021261870A1 (en) 2020-06-22 2021-06-21 Composition comprising 6'-hydroxy justcidin-b, for preventing, ameliorating or treating allergic diseases

Country Status (2)

Country Link
KR (1) KR20210157899A (en)
WO (1) WO2021261870A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102293798A (en) * 2010-06-25 2011-12-28 中国医学科学院药用植物研究所 Quality control method of justicia medicinal material
KR20160044807A (en) * 2014-10-16 2016-04-26 동화약품주식회사 Composition comprising extracts or fractions of Justicia genus
KR20170118613A (en) * 2016-04-15 2017-10-25 동화약품주식회사 Pharmaceutical Composition comprising extracts of Justicia procumbens L. for prevention or treatment of respiratory diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102293798A (en) * 2010-06-25 2011-12-28 中国医学科学院药用植物研究所 Quality control method of justicia medicinal material
KR20160044807A (en) * 2014-10-16 2016-04-26 동화약품주식회사 Composition comprising extracts or fractions of Justicia genus
KR20170118613A (en) * 2016-04-15 2017-10-25 동화약품주식회사 Pharmaceutical Composition comprising extracts of Justicia procumbens L. for prevention or treatment of respiratory diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SAVITHRAMMA, N. SULOCHANA, CH. RAO, K.N.: "Ethnobotanical survey of plants used to treat asthma in Andhra Pradesh, India", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER IRELAND LTD, IE, vol. 113, no. 1, 21 July 2007 (2007-07-21), IE , pages 54 - 61, XP022162817, ISSN: 0378-8741, DOI: 10.1016/j.jep.2007.04.004 *
SHEN QING, WANG HONGHAI, LI SHIYAN, FENG JUNLI, SONG GONGSHUAI, ZHANG YIQI, MA JIANFENG, WANG HAIXING: "Development of a mesoporous silica based solid‐phase extraction and ultra‐performance liquid chromatography–MS/MS method for quantifying lignans in Justicia procumbens", ELECTROPHORESIS, VERLAG CHEMIE, vol. 41, no. 5-6, 1 March 2020 (2020-03-01), pages 379 - 385, XP055882689, ISSN: 0173-0835, DOI: 10.1002/elps.201900401 *

Also Published As

Publication number Publication date
KR20210157899A (en) 2021-12-29

Similar Documents

Publication Publication Date Title
WO2021206309A1 (en) Pharmaceutical composition for prevention or treatment of diseases caused by sars-cov-2
WO2015002393A1 (en) Composition for treating or preventing inflammatory skin disease, comprising, as active ingredient, immature citrus fruit extract, or synephrine or salt thereof
WO2012070890A2 (en) Pharmaceutical composition comprising extract of lonicera japonica for prevention and treatment of gastroesophageal reflux disease
WO2020091440A9 (en) Composition for improving skin barrier damage and/or alleviating skin inflammation, containing 3,5-dicaffeoylquinic acid as active ingredient
WO2015005630A1 (en) Composition capable of inhibiting tslp secretion and alleviating allergic diseases
WO2015156439A1 (en) Composition for improving skin condition, comprising extract of andrographis paniculata, andrographolide or salt thereof
WO2018164325A1 (en) Composition for remedying female climacteric syndrome symptoms
WO2024071736A1 (en) Pharmaceutical composition for prevention or treatment of allergic diseases, containing dead cells of streptococcus pyogenes or spea protein
WO2021261870A1 (en) Composition comprising 6'-hydroxy justcidin-b, for preventing, ameliorating or treating allergic diseases
WO2014098306A1 (en) Pharmaceutical composition for preventing or treating dementia
WO2019209061A1 (en) Bone growth-promoting composition comprising allium fistulosum linn as active ingredient
WO2018208107A1 (en) Composition for alleviating, preventing, or treating somnipathy or composition for suppressing resistance to benzodiazepine binding site agonist of gaba-a receptor or for alleviating side-effect of benzodiazepine binding site agonist of gaba-a receptor, each composition comprising phloroglucinol as effective ingredient
WO2015034247A1 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating atopic dermatitis
WO2019031655A1 (en) Composition comprising thymol as effective ingredient for preventing or treating skin wrinkle or atopic dermatitis
WO2018174424A1 (en) Pharmaceutical composition for prevention or treatment of gynecological diseases containing extract of sarcodon imbricatus as active ingredient
WO2021080298A1 (en) Composition containing enteroccocus faecalis as active ingredient for preventing or treating obesity or metabolic syndromes induced thereby
WO2014051296A1 (en) Pharmaceutical composition, cosmetic composition and functional food composition containing extract of smilax glabra which is rhizome of smilax china for allergic diseases
WO2021261871A1 (en) Composition for preventing, ameliorating or treating respiratory diseases comprising 6'-hydroxy justicidin b
WO2016122091A1 (en) Pharmaceutical composition for prevention and treatment of allergic disease or contact dermatitis, comprising cymbidium extract as active ingredient
WO2014069836A1 (en) Histamine receptor antagonist composition containing policosanol as active ingredient
WO2023043169A1 (en) Composition containing mixed extract from artemisia argyi and saururus chinensis for preventing or treating inflammatory disease caused by ultrafine dust
WO2022250356A1 (en) Pharmaceutical composition for preventing or treating allergic diseases containing rose extract as active ingredient
WO2023003292A1 (en) Composition for preventing, ameliorating or treating skin wounds or inflammation
WO2024101570A1 (en) Antioxidant, anti-inflammatory, and anti-allergy composition containing stevia extract as active ingredient
WO2023191384A1 (en) Peptide having anti-inflammatory and anti-fibrotic activities and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21828875

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21828875

Country of ref document: EP

Kind code of ref document: A1